BOONTON, N.J., March 15, 2018 /PRNewswire/ – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, today announced that Brian Zietsman, President and Chief Financial Officer of Enteris BioPharma, will present at the 25th Annual Future Leaders in the Biotech Industry Conference being held March 23, 2018, at the Millennium Broadway Hotel & Conference Center in New York City.
Mr. Zietsman will present Enteris’ corporate growth strategy and its focus on developing orally delivered peptide therapeutics for a broad range of treatment indications. Since its founding in 2013, Enteris has advanced multiple internal and external programs leveraging its Peptelligence™ platform, a novel formulation technology that enables oral delivery of molecules that are typically injected, including peptides and BCS class II, III and IV small molecules.
Most recently, Enteris announced positive results from the Phase 2a clinical trial of Ovarest®, an oral formulation of leuprolide, for the treatment of endometriosis. Data from the study indicated that Ovarest enabled significant suppression of estradiol (E2), demonstrating a measurable pharmacodynamic effect that is tightly correlated with efficacy in endometriosis.
|Event:||25th Annual Future Leaders in the Biotech Industry Conference|
|Date:||Friday, March 23, 2018|
|Time:||2:30 p.m. (Eastern Time)|
|Location:||Millennium Broadway Hotel & Conference Center – Room 402/403|
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. The Company’s proprietary oral peptide delivery technology – Peptelligence® – has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development.
Additionally, Enteris BioPharma is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option.
Enteris BioPharma’s most advanced internal product candidate, Ovarest® (oral leuprolide tablet), is an oral peptide being developed for the treatment of endometriosis. Tobrate® (oral tobramycin tablet) is also being developed by Enteris BioPharma for the treatment of uncomplicated urinary tract infection (uUTI). A third internal compound, octreotide, will be entering preclinical development in 2018. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit https://www.EnterisBioPharma.com.
|For Enteris BioPharma:||Enteris Media Relations:|
|Brian Zietsman, President & CFO|
Tiberend Strategic Advisors, Inc.